Dynamic stromal-epithelial interactions during progression of MCF10DCIS.com xenografts

International Journal of Cancer

Volumn 120, Issue 10, 2007, Pages 2127-2134

  Tait, Larry R ^a   Pauley, Robert J ^a   Santner, Steven J ^a   Heppner, Gloria H ^a   Heng, Henry H ^b   Rak, Janusz W ^c   Miller, Fred R ^a,b  

^a KARMANOS CANCER INSTITUTE   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c RESEARCH INSTITUTE OF THE MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

Breast cancer; Carcinoma in situ; MCF10DCIS.com; Progression; Stroma; Xenograft

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; SCATTER FACTOR RECEPTOR; STROMAL CELL DERIVED FACTOR 1; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BASEMENT MEMBRANE; CANCER GROWTH; CANCER INVASION; CARCINOMA IN SITU; CELL INTERACTION; COMEDO; EPITHELIUM CELL; IMMUNE DEFICIENCY; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; INVASIVE CARCINOMA; MOUSE; MYOFIBROBLAST; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; STROMA CELL; TUMOR XENOGRAFT;

ANIMALS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CELL COMMUNICATION; DISEASE PROGRESSION; EPITHELIAL CELLS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; MICE, NUDE; MICE, SCID; PROTEIN BIOSYNTHESIS; RECEPTORS, CXCR4; STROMAL CELLS; TRANSFORMING GROWTH FACTOR BETA1; TRANSPLANTATION, HETEROLOGOUS;

EID: 34147136520     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.22572     Document Type: Article

References (43)

1. De Potter CR, Van Daele S, Van De Vijver MJ, Pauwels C, Maertens G, De Boever J, Vanderkerckhove D, Roels H. The expression of the neu oncogene product in breast lesions and in normal fetal and adult human tissues. Histopathology 1989;15:351-62.
2. Lizard-Nacol S, Lidereau R, Collin F, Arnal L, Roignot P, Cuisenier J, Guerrin J. Benign breast disease: absence of genetic alterations at several loci implicated in breast cancer malignancy. Cancer Res 1995; 55:4416-19.
3. Millikan R, Hulka B, Thor A, Zhang Y, Edgerton S, Zhang X, Pei H, He M, Wold L, Melton LJ, Ballard D, Conway K, et al. p53 mutations in benign breast tissue. J Surg Oncol 1995;13:2293-300.
4. Ramachandra S, Machin L, Ashley S, Monaghan P, Gusterson BA. Immunohistochemical distribution of c-erbB-2 in in situ breast carcinoma - a detailed morphological analysis. J Pathol 1990;161:7-14.
5. Liu E, Thor A, He M, Barcos M, Ljung BM, Benz C. The HER2 (c-erbB-2) oncogene is frequently amplified in in situ carcinomas of the breast. Oncogene 1992;7:1027-32.
6. Iglehart JD, Kerns B-J, Huper G, Marks JR. Maintenance of DNA content and erbB-2 alterations in intraductal and invasive phases of mammary cancer. Breast Cancer Res Treat 1995;34:253-63.
7. Bartkova J, Lukas J, Strauss M, Bartek J. Cyclin D1 oncoprotein aberrantly accumulates in malignancies of diverse histogenesis. Oncogene 1995;10:775-8.
8. Weinstat-Saslow D, Merino MJ, Manrow RE, Lawrence JA, Bluth RF, Wittenbel KD, Simpson JF, Page DL, Steeg PS. Overexpression of cyclin D mRNA distinguishes invasive and in situ breast carcinomas from non-malignant lesions. Nat Med 1995;1:1257-60.
9. Hwang ES, DeVries S, Chew KL, Moore DH, II, Kerlikowske K, Thor A, Ljung B-M, Waldman FM. Patterns of chromosomal alterations in breast ductal carcinoma in situ. Clin Cancer Res 2004;10:5160-7.
10. Ellsworth RE, Ellsworth DL, Dayarmin B, Hoffman LR, Love B, Hooke JA, Shriver CD. Timing of critical genetic changes in human breast disease. Ann Surg Oncol 2005;12:1054-60.
11. Kupperwasser C, Chavarria T, Wu M, Magrane G, Gray JW, Carey L, Richardson A, Weinberg RA. Reconstruction of functionally normal and malignant human breast tissues in mice. Proc Natl Acad Sci USA 2004;101:4966-71.
12. Yazhou C, Wenlv S, Weidong Z, Licun W. Clinicopathological significance of stroma fibroblasts in invasive ductal carcinoma of the breast. Tumor Biol 2004;25:290-5.
13. Miller FR, Santner SJ, Tait L, Dawson PJ. MCF10DCIS.com xenograft model of human comedo ductal carcinoma in situ. J Natl Cancer Inst 2000;92:1185-6.
14. Viloria-Petit A, Miquerol L, Yu JL, Gertsenstein M, Sheehan C, May L, Henkin J, Lobe C, Nagy A, Kerbel RS, Rak J. Contrasting effects of VEGF gene disruption in embryonic stem cell-derived versus oncogene-induced tumors. EMBO J 2003;22:4091-102.
15. Hadjantonakis AK, Gertsenstein M, Ikawa M, Okabe M, Nagy A. Generating green fluorescent mice by germline transmission of green flourescent ES cells. Mech Dev 1998;76:79-90.
16. Nagy A, Rossant J, Nagy R, Abramow-Newerly W, Roder JC. Derivation of completely cell-culture-derived mice from early-passage embryonic stem cells. Proc Natl Acad Sci USA 1993;90: 8424-8.
17. Heng HHQ, Squire J, Tsui L-C. High resolution mapping of mammalian genes by in situ hybridization to free chromatin. Proc Natl Acad Sci USA 1992;89:9509-13.
18. Heng HHQ, Tsui L-C. Modes of DAPI banding and simultaneous in situ hybridization. Chromosoma 1993;102:325-32.
19. Petersen OW, Nielsen HL, Gudjonsson T, Villadsen R, Ronnov-Jessen L, Bissell MJ. The plasticity of human breast carcinoma cells is more than epithelial to mesenchymal conversion. Breast Cancer Res 2001;3:213-17.
20. Su YC, Wu MT, Huang CJ, Hou MF, Yang SF, Chai CY. Expression of CXCR4 is associated with axillary lymph node status in patients with early breast cancer. Breast 2006;5:533-9.
21. Salvucci O, Bouchard A, Baccarelli A, Deschenes J, Sauter G, Simon R, Bianchi R, Basik M. The role of CXCR4 receptor in breast cancer: a large tissue microarray study. Cancer Res 2006;97:275-83.
22. Untergasser G, Gander R, Lilg C, Lepperdinger G, Plas E, Berger P. Profiling molecular targets of TGF-β1 in prostate fibroblast-to- myofibroblast transdifferentiation. Mech Ageing Dev 2005;126:59-69.
23. Franitza S, Kollet O, Brill A, Vaday GG, Petit I, Lapidot T, Alon R, Lider O. TGF-β1 enhances SDF-1α-induced chemotaxis and homing of naïve T cells by up-regulating CXCR4 expression and downstream cytoskeletal effector molecules. Eur J Immunol 2002;32:193-202.
24. Rifkin DB. Latent transforming growth factor-β (TGF-β) binding proteins: orchestrators of TGF-β availability. J Biol Chem 2005;280: 7409-12.
25. Shi Y, Massague J. Mechanisms of TGF-β signaling from cell membrane to the nucleus. Cell 2003;113:685-700.
26. Matteucci E, Locati M, Desiderio MA. Hepatocyte growth factor enhances CXCR4 expression favoring breast cancer cell invasiveness. Exp Cell Res 2005;310:176-85.
27. Salvucci O, Bouchard A, Baccarelli A, Deschenes J, Sauter G, Simon R, Bianchi R, Basik M. The role of CXCR4 receptor expression in breast cancer: a large tissue microarray study. Breast Cancer Research Treat 2006;97:275-83.
28. Muller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, McClanahan T, Murphey E, Yuan W, Wagner SN, Barrera JL, Mohar A, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001;410:50-6.
29. Lapteva N, Yang AG, Sanders DE, Strube RW, Chen SY. CXCR4 knockdown by small interfering RNA abrogates breast tumor growth in vivo. Cancer Gene Ther 2005;12:84-9.
30. Liang Z, Yoon Y, Votaw J, Goodman MM, Williams L, Shim H. Silencing of CXCR4 blocks breast cancer metastasis. Cancer Res 2005;65:967-71.
31. Orimo A, Gupta B, Sgroi DC, Arenzama-Seisdedos F, Delaunay T, Naeem R, Carey VJ, Richardson AL, Weinberg RA. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF1/CXCL12 secretion. Cell 2005;121:335-18.
32. Kang H, Mansel RE, Jiang WG. Genetic manipulation of stromal derived factor-1 attests the pivotal role of SDF-1-CXCR4 pathway in the aggressiveness of breast cancer cells. Int J Oncol 2005;27:1429-35.
33. Vlahakis SR, Villasis-Keever A, Gomez T, Vanegas M, Vlahakis N, Paya CV. G protein-coupled chemokine receptors induce both survival and apoptotic signaling pathways. J Immunol 2002;169:5546-54.
34. Porcile C, Bajetto A, Barbieri F, Barbero S, Bonavia R, Biglieri M, Pfrani P, Florio T, Schettini G. Stroma cell-derived factor-1α(SDF- 1α/CXCL12) stimulates ovarian cancer cell growth through the EGF receptor transactivation. Exp Cell Res 2005;308:241-53.
35. Ahr B, Denizot M, Robert-Hebmann V, Brelot A, Biard-Piechaczyk M. Identification of the cytoplasmic domains of CXCR4 involved in Jak2 and Stat3 phosphorylation. J Biol Chem 2005;280:6692-700.
36. Zhao M, DiScipio RG, Wimmer AG, Schraufstatter IU. Regulation of CXCR4-mediated nuclear translocation of extracellular signal-related kinases 1 and 2. Mol Pharmacol 2006;69:66-75.
37. Prasad A, Fernandis AZ, Rao Y, Ganju RK. Slit protein-mediated inhibition of CXCR4-induced chemotactic and chemoinvasive signaling pathways in breast cancer cells. J Biol Chem 2004;279:9115-24.
38. Chu H, Zhou H, Liu Y, Hu Y, Zhang J. Functional expression of CXC chemokine receptor-4 mediates the secretion of matrix metalloproteinases from mouse hepatocarcinoma cell lines with different lymphatic metastasis ability. Int J Biochem Cell Biol 2007;39:197-205.
39. Leivonen SK, Ala-Aho R, Koli K, Grenman R, Peltonen J, Kahari VM. Activation of Smad signaling enhances collagenase-3 (MMP-13) expression and invasion of head and neack squamous carcinoma cells. Oncogene 2006;25:2588-600.
40. Korsching E, Packeisen J, Liedtke C, Hungermann D, Wulfing P, van Diest PJ, Brandt B, Boecker W, Buerger H. The origin of vimentin expression in invasive breast cancer: epithelial-mesenchymal transition, myoepithelial histogenesis or histogenesis from progenitor cells with bilinear differentiation potential? J Pathol 2005;206:451-7.
41. de Mascarel I, MacGrogan G, Mathoulin-Pelissier S, Soubeyran I, Picot V, Coindre JM. Breast ductal carcinoma in situ with microinvasion: a definition supported by a long-term study of 1248 serially sectioned ductal carcinomas. Cancer 2002;94:2134-42.
42. Liotta LA, Kohn EC. The microenvironment of the tumour-host interface. Nature 2001;411:375-9.
43. Micke P, Ostman A. Tumor-stroma interaction: cancer-associated fibroblasts as novel targets in anti-cancer therapy? Lung Cancer 2004; 45(Suppl 2):S163-S175.